Get the Stockscreener App
2.95
5.36%
0.15
After Hours:
2.95
Lipella Pharmaceuticals Inc stock is traded at $2.95, with a volume of 184.18K.
It is up +5.36% in the last 24 hours and down -10.25% over the past month.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
See More
Previous Close:
$2.80
Open:
$2.8
24h Volume:
184.18K
Relative Volume:
1.15
Market Cap:
$3.29M
Revenue:
-
Net Income/Loss:
$-4.74M
P/E Ratio:
-4.5553
EPS:
-0.6476
Net Cash Flow:
$-3.46M
1W Performance:
+22.41%
1M Performance:
-10.25%
6M Performance:
-43.20%
1Y Performance:
-66.78%
1-Day Range:
$2.65
$3.03
1-Week Range:
$2.4001
$3.03
52-Week Range:
$2.21
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Name
Lipella Pharmaceuticals Inc
Sector
Industry
Phone
412-901-0315
Address
400 N LEXINGTON ST, PITTSBURGH
Compare LIPO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.95 | 3.29M | 0 | -4.74M | -3.46M | -0.6476 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan
Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance
LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com
Lipella Pharmaceuticals Inc (LIPO) Quarterly 10-Q Report - Quartzy
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipella issued patent by USPTO for liposomal drug delivery platform - TipRanks
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform - The Manila Times
Lipella Pharmaceuticals Secures Extended Market Exclusivity - GlobeNewswire
Lipella Pharma Secures Key Patent for Liposomal Platform, Extends Drug Pipeline Protection to 2035 | LIPO Stock News - StockTitan
China chip index nears 3-year high as TSMC order fuels self-reliance bets - Investing.com
Cathay general bancorp vice chairman sells $2.11 million in stock - Investing.com
Contrasting Wellness Center USA (OTCMKTS:WCUI) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Lipella Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com Australia
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - citybiz
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals announces 1-for-8 reverse stock split By Investing.com - Investing.com UK
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily
Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily
Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily
Recent Insider Activity Suggests Potential Gains for KE Holdings Inc ADR (BEKE) - Knox Daily
Lipella Pharmaceuticals Inc [LIPO] is -57.84% lower this YTD. Is it still time to buy? - The DBT News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Huge semiconductor deal has eyes on this tech co 👀 - RagingBull
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - GlobeNewswire
Interstitial Cystitis Market Size is Set for Rapid Growth as - openPR
Sky Quarry Announces Closing of Public Offering of $6.7 Million - The Manila Times
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Expion360 Inc’s latest rating changes from various analysts - Knox Daily
Insider Buying: Kaufman Jonathan H, Lipella Pharmaceuticals Inc [LIPO] insider invested 10,000 shares - Knox Daily
The time has not yet come to remove your chips from the table: Lipella Pharmaceuticals Inc (LIPO) - SETE News
Lipella Pharmaceuticals Inc Inc. (LIPO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - Morningstar
Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):